Drug Repurposing Series
Drug repurposing explores new therapeutic applications for existing drugs and clinical-stage compounds. Leveraging available pharmacological and clinical data may help reduce early-stage development time and costs while informing further evaluation of safety and efficacy.
Drug Repurposing Series contains compounds that have either entered clinical trial phase or have been approved. Detailed indications, clinical information and approval authorities can be provided to facilitate subsequent research.
Drug Repurposing Series contains compounds that have either entered clinical trial phase or have been approved. Detailed indications, clinical information and approval authorities can be provided to facilitate subsequent research.
-
Withdrawn Drug Compound Library233 compoundsHY-L140
-
EMA-Approved Drug Library730 compoundsHY-L116
-
Pediatric Drug Library710 compoundsHY-L104
-
Drug Repurposing Compound Library5,170 compoundsHY-L035
-
Drug Repurposing Compound Library Plus6,173 compoundsHY-L035P
-
Clinical Compound Library2,578 compoundsHY-L026
-
Clinical Compound Library Plus3,314 compoundsHY-L026P
-
NMPA-Approved Drug Library1,534 compoundsHY-L053
-
FDA-Approved Drug Library Mini3,247 compoundsHY-L022M
-
FDA-Approved Drug Library3,247 compoundsHY-L022
-
FDA-Approved Drug Library Plus3,678 compoundsHY-L022P
-
FDA Approved & Pharmacopeial Drug Library3,759 compoundsHY-L066
-
Off-patent Drug Library2,932 compoundsHY-L141
-
FDA-Approved Anticancer Drug Library1,552 compoundsHY-L122
-
Classic FDA-Approved Drug Library168 compoundsHY-L261